Imfinizi

AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results. What Happened: Imfinizi is the first line of treatment for adults with extensive-stage small-cell lung cancer in choice...